NASDAQ:WVE - Wave Life Sciences Stock Price, Price Target & More

Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."

Wave Life Sciences Ltd (NASDAQ:WVE) released its quarterly earnings results on Wednesday, May, 9th. The company reported ($1.26) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.90) by $0.36. The business earned $1.42 million during the quarter, compared to analyst estimates of $6.59 million. Wave Life Sciences had a negative net margin of 2,613.03% and a negative return on equity of 76.93%. View Wave Life Sciences' Earnings History.

Wave Life Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Wave Life Sciences.

4 equities research analysts have issued twelve-month price targets for Wave Life Sciences' stock. Their forecasts range from $40.00 to $65.00. On average, they anticipate Wave Life Sciences' stock price to reach $56.75 in the next twelve months. View Analyst Ratings for Wave Life Sciences.

Some companies that are related to Wave Life Sciences include Dr.Reddy's Laboratories (RDY), Agios Pharmaceuticals (AGIO), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Loxo Oncology (LOXO), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR), FibroGen (FGEN), Taro Pharmaceutical Industries (TARO), Madrigal Pharmaceuticals (MDGL), GW Pharmaceuticals (GWPH), Ligand Pharmaceuticals (LGND), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE) and Array Biopharma (ARRY).

Headlines about WVE stock have been trending somewhat positive this week, according to Accern. Accern identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Wave Life Sciences earned a news impact score of 0.07 on Accern's scale. They also assigned media coverage about the company an impact score of 46.90 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Wave Life Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include KAGOSHIMA SHINSANGYO SOUSEI INVESTMENT LIMITED PARTNERSHIP (8.90%), KAGOSHIMA SHINSANGYO SOUSEI INVESTMENT LIMITED PARTNERSHIP (8.90%), Redmile Group LLC (7.69%), BB Biotech AG (3.08%), BlackRock Inc. (3.01%) and Eventide Asset Management LLC (1.30%). Company insiders that own Wave Life Sciences stock include Chandra Vargeese, Chris Francis, Keith Regnante, Masaharu Tanaka, Michael A Panzara, Paul Bolno and Ra Capital Management, Llc. View Institutional Ownership Trends for Wave Life Sciences.

WVE stock was sold by a variety of institutional investors in the last quarter, including Foresite Capital Management III LLC, BlackRock Inc., Point72 Asset Management L.P., Eventide Asset Management LLC, Bailard Inc., Schwab Charles Investment Management Inc., JPMorgan Chase & Co. and A.R.T. Advisors LLC. Company insiders that have sold Wave Life Sciences company stock in the last year include Chandra Vargeese, Chris Francis, Keith Regnante, Masaharu Tanaka, Michael A Panzara and Paul Bolno. View Insider Buying and Selling for Wave Life Sciences.

WVE stock was bought by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, Artal Group S.A., DAFNA Capital Management LLC, BB Biotech AG, Platinum Investment Management Ltd., Redmile Group LLC, Citadel Advisors LLC and GSA Capital Partners LLP. View Insider Buying and Selling for Wave Life Sciences.

Shares of WVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of WVE stock can currently be purchased for approximately $38.20.

Wave Life Sciences has a market capitalization of $1.47 billion and generates $3.70 million in revenue each year. The company earns $-102,030,000.00 in net income (profit) each year or ($3.85) on an earnings per share basis. Wave Life Sciences employs 168 workers across the globe.

Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company can be reached via phone at 65-6236-3388 or via email at [email protected]